LBCL
Advertisement
Could Liso-cel Become a New Second-Line Standard for Relapsed/Refractory LBCL?
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 3, 2023
Chimeric antigen receptor (CAR) T-cell therapy with lisocabtagene maraleucel (liso-cel) significantly improved ...
Read More
Advertisement
Advertisement
Advertisement
Latest News

Pap-ctDNA Yields High Sensitivity in Endometrial Cancer

May 29, 2025

Comparative Efficacy of Therapies for Locally Advanced Cervical Cancer

May 29, 2025

Organoids Offer Insight Into Melanoma Drug Resistance

May 28, 2025

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Editorial Policy

    Advertising

    Connect

    Contact Us

    eNewsletters

    Contribute

    Career Center

    Our Network

    MashupMD

    Blood Cancers Today

    Cancer Nursing Today

    GU Oncology Now

    Urban Health Today

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |